Literature DB >> 32929628

Female sex is strongly associated with cognitive impairment in HIV infection.

Eric Andrius Coelho Duarte1, Maria Luiza Benevides2, André Luiz Pereira Martins1, Edson Pillotto Duarte1,2, Ana Beatriz Santandrea Weller1, Laura Oliveira Coutinho de Azevedo1, Maria Emília Rodrigues de Oliveira Thaís3, Jean Costa Nunes4,5,6.   

Abstract

BACKGROUND: Neurocognitive disorders remain frequent despite highly active antiretroviral treatment (HAART). The CNS is known as the sanctuary of HIV infection, where persistent neuroinflammation occurs regardless of viral suppression. Moreover, opportunistic infections, neurovascular damage and HAART neurotoxicity contribute to neurocognitive impairment. Therefore, detailed epidemiological studies might help to elucidate those complex mechanisms.
OBJECTIVE: To investigate the prevalence of cognitive impairment and the associated sociodemographic, clinical and neuropsychological variables among HIV-infected patients admitted to a tertiary centre, in southern Brazil.
METHODS: An observational, cross-sectional and analytic study was conducted between February 2019 and March 2020, in Hospital Nereu Ramos (HNR), with148 HIV-infected patients. They were interviewed, submitted to the International HIV Dementia Scale (IHDS) and had their medical data analysed.
RESULTS: The prevalence of cognitive impairment was 69.6%. It was higher among women (OR = 3.5; 95% CI 1.5-8; p < 0.01), independently of depression, educational status and age. Full years of schooling were strongly associated with IHDS scores (p < 0.01). Patient Health Questionnaire-9 (PHQ-9) scores for depression (p = 0.8), time since HIV diagnosis (p = 0.2), CD4+ cell counts (p = 0.8) and viral load (p = 0.8) were not associated with IHDS scale.
CONCLUSION: A high prevalence of cognitive impairment in HIV-infected patients was identified, independently associated with the female sex and fewer years of schooling. Further studies are needed to clarify the differences in the pathophysiology between sexes and the role of cognitive reserve in prevention of cognitive impairment in HIV infection.

Entities:  

Keywords:  AIDS; Cognitive reserve; Dementia; Female; HIV

Year:  2020        PMID: 32929628     DOI: 10.1007/s10072-020-04705-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  23 in total

1.  Prevalence of neurocognitive disorders and depression in a Brazilian HIV population.

Authors:  Flávio Trentin Troncoso; Lucieni de Oliveira Conterno
Journal:  Rev Soc Bras Med Trop       Date:  2015 Jul-Aug       Impact factor: 1.581

2.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

Review 3.  Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders.

Authors:  Dionna W Williams; Mike Veenstra; Peter J Gaskill; Susan Morgello; Tina M Calderon; Joan W Berman
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

4.  HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment.

Authors:  Deanna Saylor; Alex M Dickens; Ned Sacktor; Norman Haughey; Barbara Slusher; Mikhail Pletnikov; Joseph L Mankowski; Amanda Brown; David J Volsky; Justin C McArthur
Journal:  Nat Rev Neurol       Date:  2016-04-15       Impact factor: 42.937

5.  HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

Authors:  R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

6.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

7.  The International HIV Dementia Scale: a new rapid screening test for HIV dementia.

Authors:  Ned C Sacktor; Matthew Wong; Noeline Nakasujja; Richard L Skolasky; Ola A Selnes; Seggane Musisi; Kevin Robertson; Justin C McArthur; Allan Ronald; Elly Katabira
Journal:  AIDS       Date:  2005-09-02       Impact factor: 4.177

Review 8.  Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.

Authors:  S DeVaughn; E M Müller-Oehring; B Markey; H M Brontë-Stewart; T Schulte
Journal:  Neuropsychol Rev       Date:  2015-11-17       Impact factor: 7.444

Review 9.  Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals.

Authors:  Jonathan Underwood; Alan Winston
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

Review 10.  Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature.

Authors:  Amy R Zipursky; David Gogolishvili; Sergio Rueda; Jason Brunetta; Adriana Carvalhal; Jennifer A McCombe; M John Gill; Anita Rachlis; Ron Rosenes; Gordon Arbess; Thomas Marcotte; Sean B Rourke
Journal:  AIDS       Date:  2013-09-24       Impact factor: 4.177

View more
  2 in total

1.  The impacts of HIV infection, age, and education on functional brain networks in adults with HIV.

Authors:  Fan Nils Yang; Shiva Hassanzadeh-Behbahani; Princy Kumar; David J Moore; Ronald J Ellis; Xiong Jiang
Journal:  J Neurovirol       Date:  2022-01-19       Impact factor: 3.739

2.  Inhibitory Neurotransmission Is Sex-Dependently Affected by Tat Expression in Transgenic Mice and Suppressed by the Fatty Acid Amide Hydrolase Enzyme Inhibitor PF3845 via Cannabinoid Type-1 Receptor Mechanisms.

Authors:  Changqing Xu; Barkha J Yadav-Samudrala; Callie Xu; Bhupendra Nath; Twisha Mistry; Wei Jiang; Micah J Niphakis; Benjamin F Cravatt; Somnath Mukhopadhyay; Aron H Lichtman; Bogna M Ignatowska-Jankowska; Sylvia Fitting
Journal:  Cells       Date:  2022-03-02       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.